jivox31595@dyleris.com
dyleris.com?Make me a detailed ppt on a case presentation of peripheral vascular disease for my pg general surgery presentation from standard surgery practical and theory books covering all the viva questions
PVD Case Presentation PG Surgery
Presentation · PPTX
| Slide | Content |
|---|---|
| 1 | Title Slide — with all source books listed |
| 2 | Case Vignette — 58M, diabetic, smoker, claudication + rest pain + ulcer + gangrene (covers all 4 Fontaine stages in one case) |
| 3 | Definitions & Classification — Fontaine I–IV table with ABI values + TASC II overview |
| 4 | Aetiology & Risk Factors — all causes of PVD + risk factor table (modifiable/non-modifiable) |
| 5 | Pathophysiology — atherosclerosis step-by-step flow + haemodynamic & tissue consequences |
| 6 | Clinical Features / Symptoms — Fontaine-correlated symptom table + Leriche syndrome |
| 7 | Clinical Examination — Inspection / Palpation / Special Tests (Buerger's, Adson's, Allen's) |
| 8 | Buerger's Test + Buerger's Disease — both in one slide; Buerger's angle interpretation |
| 9 | Investigations — ABI interpretation table + Duplex, CTA, MRA, DSA, TBI, bloods |
| 10 | Acute Limb Ischaemia — 6 Ps + Embolism vs. Thrombosis comparison + Rutherford ALI |
| 11 | Medical & Endovascular Management — risk modification + antiplatelet + PTA + stenting + thrombolysis |
| 12 | Surgical Management — bypass procedures table + amputation levels + sympathectomy |
| 13 | Gangrene — Dry vs. Wet vs. Gas gangrene + Arterial vs. Venous vs. Neuropathic ulcer |
| 14 | Raynaud's Phenomenon + TOS / Cervical Rib — triphasic colour change + Adson's test |
| 15–16 | Viva Q&A (16 questions) — all classic PG surgery viva topics answered concisely |
| 17 | Summary / Key Take-home Points |
| 18 | References — Bailey & Love, S. Das, Schwartz, Sabiston, Current Surgical Therapy, TASC II |
Detailed answers according to the weightage from standard textbooks
| Q | Diagnosis/Topic | Key Points Covered |
|---|---|---|
| Q1 (20M) | Carcinoma Stomach | Arterial supply (named vessels), lymph node stations N1–N16, D1/D2 dissection, transcoelomic spread; Aetiology (H. pylori/Correa cascade, dietary, genetic), Borrmann + Laurén classification, EGC vs. advanced, TNM staging 8th ed.; Surgery (subtotal/total gastrectomy, D2), FLOT chemotherapy, Trastuzumab, Palliative options |
| Q2 (20M) | Congenital Kidney Anomalies + PUJO | Complete CAKUT classification (agenesis, ectopia, horseshoe, ADPKD, MCDK, duplex, retrocaval ureter); PUJO intrinsic/extrinsic causes, Dietl's crisis, DTPA renogram (DRF <40%, T½ >20 min), Anderson-Hynes pyeloplasty, HoLEP endopyelotomy, laparoscopic/robotic repair |
| Q3 (20M) | Penetrating Abdominal Trauma | MLC documentation checklist (entry/exit wound description, police intimation, chain of evidence); ATLS primary survey; Stab vs. GSW; FAST, CT, DPL, DL; Damage control surgery (lethal triad); Organ-specific management |
| Q4a (10M) | Post-LSCS DVT | Virchow's triad in pregnancy, hypercoagulable state, clinical features (Homan's, Moses', phlegmasia); Wells score; Duplex USS; LMWH (Enoxaparin), duration, prevention |
| Q4b (10M) | Chronic Pancreatitis + Steatorrhoea | TIGAR-O aetiology, alcohol mechanism, exocrine insufficiency (90% loss), faecal elastase, MRCP "chain of lakes"; PERT (Creon), alcohol cessation, Lateral PJ (Puestow/Frey), Beger procedure, Whipple's |
| Q5a (10M) | Recent Advances Ventral Hernia | Biological/biosynthetic/anti-adhesion meshes, laparoscopic IPOM Plus, robotic rTAPP/eTEP, TAR (posterior CST), botulinum toxin, ERAS, Rives-Stoppa |
| Q5b (10M) | LASER in Uro-Ano-Rectal | HoLEP, Greenlight (PVP), ThuVEP for BPH; Ho:YAG lithotripsy, TFL for stones; HeLP/LHP for haemorrhoids; FiLaC for fistula-in-ano; SiLaC for pilonidal sinus; CO₂ for anal warts |
Smoking index
Smoking Index (SI) = Number of cigarettes smoked per day × Number of years of smoking
| Smoking Index | Interpretation |
|---|---|
| < 100 | Low risk |
| 100 – 299 | Moderate risk — monitor |
| ≥ 300 | Significant risk — COPD, chronic bronchitis, peripheral vascular disease |
| ≥ 400 | High risk for lung carcinoma |
Pack-Years = (Cigarettes smoked per day ÷ 20) × Number of years smoked
| Pack-Years | Clinical Relevance |
|---|---|
| ≥ 10 pack-years | Threshold for HPV+ head & neck cancer risk stratification |
| ≥ 20 pack-years | Lung cancer screening eligibility (USPSTF / NLST criteria) |
| > 30 pack-years | Strong COPD risk (Robbins Pathology) |
| > 40 pack-years | Very high COPD / lung malignancy risk |
Hyperasthesia in peripheral arterial disease
"Sensation of the gangrenous area is often lost. The patient is unable to move the part when the viability of the deeper tissues becomes at stake. On the border line of the gangrene the skin becomes hyperaesthetic." — S. Das, Chapter 6: Peripheral Vascular Disease, p. 92
| Feature | Significance |
|---|---|
| Hyperaesthesia at border | Marks the demarcation line — helps define extent of gangrene |
| Anaesthesia of core | Confirms non-viability of gangrenous tissue |
| Useful for amputation planning | Amputate at or proximal to the zone of normal sensation to ensure tissue viability |
| Distinguishes dry from early wet gangrene | Wet gangrene may show broader zone of hyperaesthesia due to spreading infection and inflammation |
| Prognostic value in acute limb ischaemia | Presence of paraesthesia/anaesthesia = severe ischaemia (Rutherford IIb/III); neurological deficit → irreversible ischaemia impending |
Proximal viable tissue Border zone Gangrenous core
↓ ↓ ↓
Normal sensation HYPERAESTHESIA ANAESTHESIA
(sensitised nociceptors, (nerves dead /
inflammatory mediators) non-functional)